{"id":"W4293652654","doi":"10.1016/j.jtct.2022.08.021","title":"Ibrutinib Treatment of Pediatric Chronic Graft-versus-Host Disease: Primary Results from the Phase 1/2 iMAGINE Study","year":2022,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"Janssen Pharmaceuticals; Incyte; Fondazione IRCCS Policlinico San Matteo; Pharmacyclics; AbbVie; Jazz Pharmaceuticals; Novartis; Teva Pharmaceutical Industries; Gilead Sciences; GlaxoSmithKline; Amgen","keywords":"Ibrutinib; Medicine; Internal medicine; Clinical endpoint; Hematopoietic stem cell transplantation; Adverse effect; Refractory (planetary science); Graft-versus-host disease; Transplantation; Gastroenterology; Clinical trial; Leukemia; Chronic lymphocytic leukemia","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002386239,0.000855879,0.001387883,0.0002211444,0.0001660149,0.0005920011,0.0004058031,0.0003535161,0.001059393],"category_scores_gemma":[0.001097568,0.0002757727,0.0008939872,0.0002972455,0.0003737764,0.0004358956,0.0003879082,0.001411857,0.0002378407],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005078653,"about_ca_system_score_gemma":0.0007268518,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000401682,"about_ca_topic_score_gemma":0.001172848,"domain_scores_codex":[0.9994393,0.0003065671,0.00003137182,0.00006617895,0.00009352454,0.000063113],"domain_scores_gemma":[0.999353,0.0001116212,0.0002399342,0.000055242,0.00005689288,0.0001832987],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4418251,0.02696279,0.08030017,0.002576202,0.004976162,0.001040001,0.0005949095,0.009986289,0.1118535,0.001024603,0.02257917,0.2962811],"study_design_scores_gemma":[0.3035694,0.3600338,0.2443233,0.000423616,0.0053511,0.004530307,0.000220852,0.006276693,0.02452071,0.0005691712,0.05004283,0.0001382162],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9804607,0.01131834,0.001039885,0.0003483534,0.00005459843,0.000823273,0.003160113,0.00009606708,0.002698795],"genre_scores_gemma":[0.9763084,0.007527067,0.003129866,0.0007673698,0.0001995338,0.001014394,0.01017555,0.00006744681,0.0008104172],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002386239,"threshold_uncertainty_score":0.01261979,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04040375757232324,"score_gpt":0.3183749669695803,"score_spread":0.2779712093972571,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}